BioSpace News Archive

Wilmington, Delaware, United States, Transparency Market Research Inc. – The global rare disease gene therapy is expected to witness a significant growth in the forecast period, 2020-2030 on account of the increasing cases of genetic diseases worldwide.

Wilmington, Delaware, United States, Transparency Market Research Inc. – Products in the global next generation wound closure device market are expected to witness several lucrative opportunities in the coming years owing to their rapid adoption and now high utilization in various surgical procedures.

The growth in the Huntington’s disease treatment market has been growing rapidly because of a lot of factors.

Aerie Pharmaceuticals, Inc. announced that the compensation committee of Aerie Pharmaceutical’s board of directors granted one new employee an award totaling 16,900 stock options that will vest over 4 years, with 25% vesting on the first anniversary of the hire date and the remainder vesting ratably on each of the subsequent 36 monthly anniversaries of the hire date.

atai Life Sciences N.V., a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that the company has entered into a term loan facility for up to $175 million with Hercules Capital, Inc..

Protalix BioTherapeutics, Inc. reported financial results for the second quarter ended June 30, 2022 and provided a business update on recent corporate and regulatory developments.

Genprex, Inc. today announced that the Safety Review Committee (SRC) has approved continuation of the Acclaim-1 Phase 1/2 clinical trial of REQORSA™ in combination with Tagrisso® (osimertinib) to treat late-stage non-small cell lung cancer (NSCLC) following a review of the first cohort of patients in the Phase 1 portion of the trial.

GreenLight Biosciences today reported operational highlights and financial results for the second quarter ended June 30, 2022.

BD and Accelerate Diagnostics, Inc. announced a worldwide commercial collaboration agreement where BD will offer Accelerate’s rapid testing solution for antibiotic resistance and susceptibility offering results in hours, versus one to two days with some traditional laboratory methods.

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced its financial results for the second quarter of 2022 and provided a business and clinical update.